Zidovudine/Lamivudine
Small molecule
GileadZidovudine/Lamivudine is one of 11 small molecule programs targeting Myelopathy. It is currently in development.
1
Indications
4
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Myelopathy
#DrugCompanyPhaseTrials
1Immunoglobulin
SanofiApproved
Prialt
TTerezinha de Jesus Esteves Barata
Approved
Rilutek
AAzurity Pharmaceuticals
Phase 3
Rituxan
RochePhase 2
Ibudilast
UUniversity of California, Los Angeles
Phase 3
KW-0761
Kyowa Kirin Co., Ltd.Phase 3
Methionine
SSt. Jude Children's Research Hospital
Phase 3
Limaprost
SSeoul National University Hospital
Phase 3
NK Cells
SSouthwest Hospital, China
Phase 1
MT-3921
Tanabe Pharma CorporationPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Drug1 trial
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00074581·3,526 enrolled
Adult1 trial
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting
Completed·—·Phase 4·NCT01772940·425 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zidovudine/Lamivudine. EMBL-EBI & Wellcome Sanger Institute.
- [4]